Figure 4
Figure 4. PRC2 suppresses the development of B-cell lymphoma in Eμ-myc transgenic mice in a cell autonomous manner. (A) Lymphoma-free survival of Eμ-myc (circle), Eμ-myc/Suz12Plt8/+ (square), and Eμ-myc/Bmi1+/− (triangle) mice. (B) Immunoblot analysis of primary lymphomas from Eμ-myc and Eμ-myc/Suz12Plt8/+ mice. (C) Lymphoma-free survival of lethally irradiated Ly5.1 recipient mice reconstituted with Eμ-myc fetal liver cells expressing shRNA to Suz12 (circle), Ezh2 (triangle), and a Nons control (square). (D) Immunoblot analysis of Suz12, Ezh2, and H3K27me3 from FACS-sorted donor-derived lymphoma cells expressing the indicated shRNAs.

PRC2 suppresses the development of B-cell lymphoma in Eμ-myc transgenic mice in a cell autonomous manner. (A) Lymphoma-free survival of Eμ-myc (circle), Eμ-myc/Suz12Plt8/+ (square), and Eμ-myc/Bmi1+/− (triangle) mice. (B) Immunoblot analysis of primary lymphomas from Eμ-myc and Eμ-myc/Suz12Plt8/+ mice. (C) Lymphoma-free survival of lethally irradiated Ly5.1 recipient mice reconstituted with Eμ-myc fetal liver cells expressing shRNA to Suz12 (circle), Ezh2 (triangle), and a Nons control (square). (D) Immunoblot analysis of Suz12, Ezh2, and H3K27me3 from FACS-sorted donor-derived lymphoma cells expressing the indicated shRNAs.

Close Modal

or Create an Account

Close Modal
Close Modal